InChI
1S/C20H23N7O7.Ca/c21-20-25-16-15(18(32)26-20)27(9-28)12(8-23-16)7-22-11-3-1-10(2-4-11)17(31)24-13(19(33)34)5-6-14(29)30;/h1-4,9,12-13,22H,5-8H2,(H,24,31)(H,29,30)(H,33,34)(H4,21,23,25,26,32);/q;+2/p-2/t12?,13-;/m0./s1
SMILES string
[Ca++].[H]O[H].[H]C(=O)N1C(CNc2ccc(cc2)C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)CNc3nc(N)nc(O)c13
InChI key
KVUAALJSMIVURS-ZEDZUCNESA-L
biological source
synthetic
grade
pharmaceutical primary standard
agency
EP
API family
folic acid
form
solid
manufacturer/tradename
EDQM
technique(s)
gas chromatography (GC): suitable, liquid chromatography (LC): suitable
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-8°C
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia. Calcium folinate (CF) is a folic acid derivative. It is a naturally occurring compound that has a vital role in various metabolic pathways. Calcium folinate (CF) drug is also used in the treatment of anemia, during pregnancy.
Application
叶酸拮抗剂通过结合二氢叶酸还原酶并阻滞叶酸转化为四氢叶酸盐发挥作用，而亚叶酸钙则可抵消叶酸拮抗剂的作用。在医学上，亚叶酸钙在甲氨蝶呤治疗后用于降低甲氨蝶呤的毒性。亚叶酸钙还可用于增强癌症治疗中 5-氟尿嘧啶的细胞毒性效应。
Packaging
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
Other Notes
Sales restrictions may apply.
存储类别
11 - Combustible Solids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
LC- MS characterization of trace impurities contained in calcium folinate
Francese G, et al.
Journal of Pharmaceutical and Biomedical Analysis, 39(3-4), 757-763 (2005)
Harpreet Wasan et al.
The Lancet. Oncology, 15(6), 631-639 (2014-04-08)
Advanced colorectal cancer is treated with a combination of cytotoxic drugs and targeted treatments. However, how best to minimise the time spent taking cytotoxic drugs and whether molecular selection can refine this further is unknown. The primary aim of this
Akira Ooki et al.
Japanese journal of clinical oncology, 44(4), 383-387 (2014-02-22)
We have planned a multicentre prospective study to examine the relative impact of the efficacy and adverse events of cetuximab plus first-line chemotherapy on the quality of life in Japanese patients with KRAS wild-type unresectable colorectal cancer. The Dermatology Life
High cut-off dialysis as a salvage therapy option in high-dose methotrexate chemotherapy?
Anna Bertram et al.
Annals of hematology, 93(6), 1053-1055 (2013-10-08)
Zheng-mao Lu et al.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 35(4), 2941-2948 (2013-12-10)
Polymorphisms in the excision repair cross-complimentary group 1 (ERCC1)-excision repair cross-complimentary group 4 (ERCC4) genes have been implicated in the prognosis of various cancers. We conducted a cohort study to investigate the role of ERCC1-ERCC4 gene polymorphisms on the response
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持